Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
induced pluripotent stem cell-derived natural killer T cells
- Development stage
- Unknown
- Lead developer
- BrightPath Biotherapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial, Intravenous
01
Overview
Induced pluripotent stem cell-derived natural killer T cells (iPSC-iNKT cells) are an allogeneic cellular immunotherapy consisting of invariant natural killer T (iNKT) cells generated from induced pluripotent stem cells (iPSCs). These cells are designed to bridge innate and adaptive immunity by recognizing glycolipid antigens, such as alpha-galactosylceramide (α-GalCer), presented by CD1d molecules. Upon activation, iPSC-iNKT cells produce high levels of interferon-gamma (IFN-γ), which activates other immune cells like NK cells and CD8+ T cells to exert anti-tumor effects. The therapy is being developed primarily by RIKEN and the Japan Agency for Medical Research and Development (AMED) for the treatment of recurrent or advanced head and neck squamous cell carcinoma. In clinical trials, they are often administered in combination with α-GalCer-pulsed dendritic cells to enhance their activation and therapeutic efficacy.
- Other names
- iPSC-derived invariant natural killer T cells
02
Targets
CD1D (Tumor-associated macrophage/myeloid-derived suppressor cell CD1d complex)α-GalCer/CD1d (Alpha-galactosylceramide-CD1d complex)
Beyond the preview
Go deeper on induced pluripotent stem cell-derived natural killer T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on induced pluripotent stem cell-derived natural killer T cells.